Attovia Therapeutics/$ATTO
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Attovia Therapeutics
Attovia Therapeutics Inc is a clinical stage biotechnology company focused on research and development of therapeutic products in the fields of immune-mediated diseases. Its product pipeline includes ATTO-1310 and ATTO-2306 for immune-dermatology indications and ATTO-1091 for inflammatory diseases, including inflammatory bowel disease (IBD). The company's product candidates are developed using its ATTOBODY biologics platform.
- Ticker
- $ATTO
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 44
- Headquarters
- San Carlos, United States
- Website
- www.attovia.com
ATTO Metrics
BasicAdvanced
$764M
-
-$7.49
-
-
Price and volume
Market cap
$764M
52-week high
$28.00
52-week low
$12.94
Average daily volume
349K
Financial strength
Current ratio
34.66
Quick ratio
33.925
Long term debt to equity
0.004
Total debt to equity
0.01
Profitability
EBITDA (TTM)
-84.648
Gross margin (TTM)
-4,925.97%
Net profit margin (TTM)
-5,477.22%
Operating margin (TTM)
-5,945.49%
Revenue per employee (TTM)
$30,000
Management effectiveness
Valuation
Price to revenue (TTM)
122.358
Price to book
1.92
Price to tangible book (TTM)
1.92
Price to free cash flow (TTM)
-2.248
Free cash flow yield (TTM)
-44.48%
Free cash flow per share (TTM)
-7.442
Growth
What the Analysts think about ATTO
Analyst ratings (Buy, Hold, Sell) for Attovia Therapeutics stock.
Analyst projections of the future price of Attovia Therapeutics stock.
Bulls say / Bears say
Preliminary Phase 1b results suggest ATTO-1310 can deliver rapid itch relief in chronic pruritus and high-itch atopic dermatitis, with lesion control also reported in AD. This is an early human signal ahead of larger Phase 2 trials. (Attovia Therapeutics)
The upsized IPO brought in about $305 million in net proceeds, and Attovia expects its cash to fund operations into 2030. This gives it time to run planned ATTO-1310 Phase 2 studies and advance other candidates without an immediate financing overhang. (Attovia Therapeutics)
Attovia has further candidates beyond its lead: ATTO-2306 combines IL-31 and IL-13 for inflammatory skin disease, while ATTO-1091 targets three IBD pathways. Both are planned to enter Phase 1 in the first half of 2027, offering potential pipeline breadth if development succeeds. (Attovia Therapeutics)
The ATTO-1310 efficacy evidence remains preliminary: the Phase 1 study was small and designed mainly to assess safety and early signals, with rescue therapy allowed after week four. Those early responses may not translate into benefit in larger, controlled trials. (Investing.com)
Attovia faces established rivals: Nemluvio competes in itch, ATTO-2306 would have to challenge Dupixent in dermatitis, and ATTO-1091 enters a crowded IBD market. The company will need to show a meaningful advantage to win share in these areas. (Fierce Biotech)
Attovia has no approved products or product-sales revenue and continues to report operating losses; second-quarter R&D spending rose to $18.9 million from $13.6 million a year earlier. Spending may increase as it advances its trials, despite the stated cash runway into 2030. (SEC, Attovia Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 26 Oct 2026.
ATTO Financial Performance
Revenues and expenses
ATTO Earnings Performance
Company profitability
Upcoming events
No upcoming events
ATTO News
AllArticlesVideos
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.